Texas Tech QB Brendan Sorsby’s Gambling Addiction Treatment Highlights a Growing Public Health Crisis—What the Science Says About Recovery and Eligibility
In this week’s sports and public health intersection, Texas Tech quarterback Brendan Sorsby has entered treatment for gambling addiction, casting doubt on his eligibility for the 2026 season. This case isn’t just about one athlete—it’s a microcosm of a rising epidemic affecting millions, with profound neurological, psychological and societal consequences. Here’s what the evidence reveals about gambling disorder, its treatment pathways, and the broader implications for athletes and the general public.
The Neuroscience of Gambling Addiction: Why It’s Not Just “Bad Decisions”
Gambling disorder (GD) is recognized by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as a behavioral addiction, sharing striking similarities with substance use disorders. Functional MRI studies show that gambling activates the brain’s reward system—specifically the ventral striatum and prefrontal cortex—in ways nearly identical to cocaine or alcohol. Over time, chronic gambling leads to dopamine dysregulation, impairing impulse control and decision-making (JAMA Psychiatry, 2013).
For athletes like Sorsby, the stakes are even higher. A 2022 study in The Lancet Psychiatry found that elite athletes are 2-3 times more likely to develop GD than the general population, due to risk-taking traits, financial pressures, and access to betting platforms (The Lancet Psychiatry, 2022). The NCAA’s 2023 survey revealed that 16% of male college athletes reported gambling on sports in the past year, despite strict regulations.
“Gambling disorder is a chronic, relapsing condition, not a moral failing. The brain changes we observe in GD patients are comparable to those in heroin addiction. Recovery requires structured intervention—just as we’d treat diabetes or hypertension.”
In Plain English: The Clinical Takeaway
- Gambling addiction rewires the brain’s reward system, making it as hard to quit as drugs or alcohol. It’s not about willpower.
- Athletes are at higher risk due to competitive traits and easy access to betting apps. The NCAA’s 2023 data shows 1 in 6 male college athletes gambles on sports.
- Treatment works, but relapse rates are high (50-60% within a year) without ongoing support, per Addiction Science & Clinical Practice.
Treatment Pathways: What Works (and What Doesn’t)
Sorsby’s treatment likely involves a combination of cognitive behavioral therapy (CBT), medication, and peer support. Here’s the evidence behind each approach:
| Treatment | Mechanism of Action | Efficacy (Phase III Trials) | Side Effects/Contraindications |
|---|---|---|---|
| CBT (Cognitive Behavioral Therapy) | Targets maladaptive thought patterns (e.g., “I’ll win next time”) and teaches coping skills. | 45-60% reduction in gambling behavior at 12 months (JAMA, 2017). | None; requires active participation. |
| Naltrexone (Opioid antagonist) | Blocks mu-opioid receptors, reducing cravings and reward sensations. | 30-40% reduction in gambling urges vs. Placebo (NEJM, 2020). | Nausea, headache, liver toxicity (contraindicated in severe liver disease). |
| Nalmefene (Opioid modulator) | Similar to naltrexone but with longer half-life and fewer liver risks. | 25-35% reduction in gambling days (The Lancet Psychiatry, 2021). | Dizziness, insomnia; contraindicated in renal impairment. |
| Gamblers Anonymous (GA) | 12-step program with peer support and accountability. | 30% abstinence at 1 year (self-reported; Journal of Gambling Studies, 2015). | No side effects; effectiveness varies by individual. |
Funding transparency: The NEJM naltrexone trial was funded by the National Institute on Drug Abuse (NIDA), a federal agency with no industry ties. The Lancet Psychiatry study on nalmefene was supported by Lundbeck, the drug’s manufacturer, which may introduce bias. Always cross-check funding sources in clinical research.
Geographic Disparities: How the U.S., UK, and EU Treat Gambling Addiction
The response to GD varies dramatically by region, affecting access to care and public health outcomes:
- United States: The FDA has not approved any drugs specifically for GD, though naltrexone and nalmefene are used off-label. Insurance coverage for therapy is inconsistent, with only 19 states mandating coverage for addiction treatment (KFF, 2025). The NCAA’s 2024 policy bans all sports betting for athletes but offers no standardized treatment protocols for those who relapse.
- United Kingdom: The NHS provides free CBT and medication through its National Problem Gambling Clinic, funded by a mandatory levy on betting companies. A 2023 study in BMJ found that UK treatment programs have a 65% success rate at 12 months, the highest in the world (BMJ, 2023).
- European Union: The EMA approved nalmefene for GD in 2024, making it the first (and only) drug with an official indication for gambling disorder. However, access varies by country—Germany and France cover it under national health systems, while Spain and Italy do not.
“The UK’s model proves that treating gambling addiction as a public health issue—rather than a personal failing—saves lives and money. The U.S. Lags behind, with fragmented care and punitive policies that discourage athletes from seeking help.”
The NCAA’s Dilemma: Punishment vs. Rehabilitation
Sorsby’s case exposes a critical flaw in the NCAA’s approach to gambling. While the association bans all sports betting for athletes, its penalties are disproportionately punitive compared to its support systems. A 2025 report by the Knight Commission on Intercollegiate Athletics found that:
- Of the 127 athletes suspended for gambling violations since 2020, only 18% received mental health support from their universities.
- Black athletes are 3.5 times more likely to be suspended for gambling than white athletes, despite similar rates of gambling behavior (Knight Commission, 2025).
- The NCAA’s lack of a standardized treatment protocol leaves athletes like Sorsby in limbo—eligible for care but with no clear path to reinstatement.
The NCAA’s 2026 eligibility rules state that athletes who “voluntarily seek treatment” for GD may petition for reinstatement, but the process is opaque and inconsistent. Contrast this with the NFL, which has a confidential treatment program for gambling addiction, allowing players to return after completing a 12-week rehabilitation protocol.
Contraindications & When to Consult a Doctor
Gambling disorder is a medical condition, not a choice. If you or someone you know exhibits these signs, seek professional help immediately:
- Red flags:
- Spending more money or time gambling than intended.
- Lying to family/friends about gambling habits.
- Chasing losses (betting more to “win back” money).
- Neglecting work, school, or relationships due to gambling.
- When to seek emergency care:
- Expressing suicidal thoughts or self-harm (GD patients are 15 times more likely to attempt suicide; JAMA Network Open, 2018).
- Experiencing severe withdrawal symptoms (e.g., anxiety, insomnia, irritability) when unable to gamble.
- Who should avoid certain treatments:
- Naltrexone/nalmefene: Contraindicated in patients with severe liver or kidney disease. Consult a doctor if you have a history of opioid use (these drugs can precipitate withdrawal).
- CBT: Not recommended for individuals with untreated psychosis or severe depression without concurrent psychiatric care.
The Future of Gambling Addiction Treatment: What’s on the Horizon?
Research into GD is accelerating, with several promising avenues:
- Psychedelic-assisted therapy: A Phase II trial at Johns Hopkins is testing psilocybin (the active compound in “magic mushrooms”) combined with CBT for GD. Early data suggests a 50% reduction in cravings after a single dose (ClinicalTrials.gov, 2026).
- Digital therapeutics: Apps like BetBlocker (FDA-cleared in 2025) use AI to block gambling sites and provide real-time CBT interventions. A 2026 study in Nature Digital Medicine found that app users were 2.3 times more likely to remain abstinent at 6 months (Nature, 2026).
- Neurofeedback: Emerging research at UCLA uses EEG biofeedback to train patients to regulate their brain’s reward response. A pilot study showed a 40% reduction in gambling urges after 10 sessions (Frontiers in Psychiatry, 2024).
For athletes like Sorsby, the path forward is uncertain. The NCAA’s lack of a clear rehabilitation protocol means his eligibility hinges on factors outside his control. But his case could catalyze change—pushing institutions to treat GD as the medical condition it is, rather than a disciplinary issue.
References
- JAMA Psychiatry. (2013). Neural correlates of pathological gambling in a sample of community gamblers.
- The Lancet Psychiatry. (2022). Gambling disorder in elite athletes: A systematic review.
- NEJM. (2020). Naltrexone for the treatment of gambling disorder.
- BMJ. (2023). Effectiveness of NHS gambling treatment services in England.
- Knight Commission on Intercollegiate Athletics. (2025). Gambling and college athletes: A crisis of policy and care.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. If you or someone you know is struggling with gambling addiction, consult a licensed healthcare provider or contact the National Problem Gambling Helpline (1-800-522-4700).
